Pitavastatin slows tumor progression and alters urine‐derived volatile organic compounds through the mevalonate pathway

Abstract

Bone is a frequent site of metastasis from breast cancer, and a desirable drug could suppress tumor growth as well as metastasis‐linked bone loss. Currently, no drug is able to cure breast cancer‐associated bone metastasis. In this study, we focused on statins that are known to inhibit cholesterol production and act as antitumor agents. After an initial potency screening of 7 U.S. Food and Drug Administration‐approved statins, we examined pitavastatin as a drug candidate for inhibiting tumor and tumor‐induced bone loss. In vitro analysis revealed that pitavastatin acted as an inhibitor of tumor progression by altering stress to the endoplasmic reticulum, down‐regulating peroxisome proliferator‐activated receptor γ, and reducing Snail and matrix metalloproteinase 9. In bone homeostasis, it blocked osteoclast development by suppressing transcription factors c‐Fos and JunB, but stimulated osteoblast mineralization by regulating bone morphogenetic protein 2 and p53. In a mouse model, pitavastatin presented a dual role in tumor inhibition in the mammary fat pad, as well as in bone protection in the osteolytic tibia. In mass spectrometry‐based analysis, volatile organic compounds (VOCs) that were linked to lipid metabolism and cholesterol synthesis were elevated in mice from the tumor‐grown placebo group. Notably, pitavastatin‐treated mice reduced specific VOCs that are linked to lipid metabolites in the mevalonate pathway. Collectively, the results lay a foundation for further investigation of pitavastatin s therapeutic efficacy in tumor‐induced bone loss, as well as VOC‐based diagnosis of tumor progression and treatment efficacy.—Wang, L., Wang Y., Chen, A., Teli, M., Kondo, R. Jalali A. Fan Y. Liu S. Zhao X. Siegel A. Minami K. Agarwal M. Li B.‐Y., Yokota, H. Pitavastatin slows tumor progression and alters urine‐derived volatile organic compounds through the mevalonate pathway. FASEB J. 33, 13710‐13721 (2019). www.fasebj.org